Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Colorectal Cancer: New Diagnostic and Therapeutic Approaches 2.0
share announcement

Colorectal Cancer: New Diagnostic and Therapeutic Approaches 2.0

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 4304

Special Issue Editors

Prof. Dr. Antonio Biondi

grade E-Mail Website
Guest Editor
Department of General Surgery and Surgical - Medical Specialties, University of Catania, Catania, Italy
Interests: colorectal cancer; general surgery; screening; biomarkers; quality of life; liquid biopsy; microbiota
Special Issues, Collections and Topics in MDPI journals
Dr. Marco Vacante

E-Mail Website
Guest Editor
Department of General Surgery and Surgical - Medical Specialties, University of Catania, Catania, Italy
Interests: colorectal cancer; elderly care; nutrition; quality of life; liquid biopsy; cancer biomarkers; microbiota
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, “Colorectal Cancer: New Diagnostic and Therapeutic Approaches”, will mainly focus on novel and promising tools for the management of colorectal cancer (CRC). Research is moving towards the detection of accurate and personalized biomarkers with high specificity and sensitivity in patients with CRC, by means of the so-called “liquid biopsy”. Liquid biopsies have been demonstrated to improve CRC screening and diagnosis, predict relapse and metastasis, and allow the assessment of minimal residual disease and resistance to chemotherapy. Furthermore, gut microbiota have shown potential utility in the diagnosis and treatment of CRC. The host−microbe interplay in CRC and the promotion of homeostatic immune response using microbe-targeted therapies could be helpful in preventing and/or treating CRC development. There is an essential need for new therapeutic approaches in patients with CRC, such as the development of more active and tolerable chemotherapy regimens that could help us overcome some of the therapeutic challenges of CRC.

We invite authors to submit original research and review articles that focus on this significant and fast-progressing field of medicine. Potential topics include, but are not limited to:

  •  Liquid biopsy;
  • Biomarkers;
  • The role of gut microbiota in the diagnosis and treatment of CRC;
  • Diagnosis and therapy of CRC;
  • Recent advances in CRC therapies.

Prof. Dr. Antonio Biondi
Dr. Marco Vacante
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • liquid biopsy
  • microbiota
  • screening
  • chemotherapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 1026 KiB  
Article
Comparison between Peritumoral and Intratumoral Budding in Colorectal Cancer
by Jung-Soo Pyo, Ji Eun Choi, Nae Yu Kim, Kyueng-Whan Min and Dong-Wook Kang
Biomedicines 2024, 12(1), 212; https://doi.org/10.3390/biomedicines12010212 - 17 Jan 2024
Viewed by 717
Abstract
Tumor budding (TB) is classified, based on location, into peritumoral budding (PTB) or intratumoral budding (ITB). This study aimed to evaluate the relationship between PTB and ITB in colorectal cancers (CRCs). PTB and ITB were investigated and subsequently divided into high and low [...] Read more.
Tumor budding (TB) is classified, based on location, into peritumoral budding (PTB) or intratumoral budding (ITB). This study aimed to evaluate the relationship between PTB and ITB in colorectal cancers (CRCs). PTB and ITB were investigated and subsequently divided into high and low groups. CRCs were divided into three groups: (1) high PTB/ITB, (2) high PTB or ITB, and (3) low PTB/ITB. The clinicopathological and prognostic significances were evaluated according to the three tumor budding (TB) groups. High PTB/ITB and low PTB/ITB were identified in 32 (12.0%) and 135 (50.8%) patients, respectively. A total of 99 patients (37.2%) were found to have high PTB or ITB. TB was significantly correlated with lymphatic and perineural invasion, lymph node metastasis, metastatic lymph node ratio, distant metastasis, and a higher pTNM stage. A significant correlation was found between high PTB and high ITB (p = 0.010). The amount of PTB was found to increase significantly with the amount of ITB (p < 0.001) in a linear regression test. Patients with high PTB/ITB had worse overall and recurrence-free survival than those with high PTB or ITB. Conversely, patients with low PTB/ITB had better overall and recurrence-free survival rates than those with high PTB or ITB. However, there was no significant difference in overall and recurrence-free survival between patients with high PTB/low ITB and high ITB/low PTB (p = 0.336 and p = 0.623, respectively). In summary, the presence of TB, regardless of PTB or ITB, was significantly correlated with aggressive tumor behavior and a worse prognosis than the absence of TB. Additionally, the present study demonstrated that it is feasible to stratify the prognosis of patients based on whether they have both PTB and ITB or only one of the two. Full article
(This article belongs to the Special Issue Colorectal Cancer: New Diagnostic and Therapeutic Approaches 2.0)
►▼ Show Figures

Figure 1

11 pages, 2557 KiB  
Article
miR-200b, ZEB2 and PTPN13 Are Downregulated in Colorectal Carcinoma with Serosal Invasion
by Branislava Ranković, Emanuela Boštjančič, Nina Zidar, Margareta Žlajpah and Jera Jeruc
Biomedicines 2022, 10(9), 2149; https://doi.org/10.3390/biomedicines10092149 - 01 Sep 2022
Cited by 5 | Viewed by 1229
Abstract
Serosal invasion is an independent negative prognostic factor in certain cancers, including CRC. However, the mechanisms behind serosal invasion are poorly understood. We therefore assumed that epithelial-mesenchymal transition (EMT) might be involved. Our study included 34 patients with CRC, 3 stage pT2, 14 [...] Read more.
Serosal invasion is an independent negative prognostic factor in certain cancers, including CRC. However, the mechanisms behind serosal invasion are poorly understood. We therefore assumed that epithelial-mesenchymal transition (EMT) might be involved. Our study included 34 patients with CRC, 3 stage pT2, 14 stage pT3 and 17 showing serosal invasion (stage pT4a according to TNM staging system). RNA isolated from formalin-fixed paraffin-embedded tissue samples was analysed for expression of the miR-200 family and their target genes CDKN1B, ONECUT2, PTPN13, RND3, SOX2, TGFB2 and ZEB2 using real-time PCR. We found upregulation of miR-200b and ONECUT2 in CRC pT3 and pT4a compared to normal mucosa, and downregulation of CDKN1B in CRC pT3. Moreover, we observed, downregulation of miR-200b, PTPN13 and ZEB2 in CRC with serosal invasion (pT4a) compared to pT3. Our results suggest the involvement of partial EMT in serosal invasion of CRC. In addition, PTPN13 seems to be one of the important regulators involved in serosal invasion, and ONECUT2 in tumour growth. Full article
(This article belongs to the Special Issue Colorectal Cancer: New Diagnostic and Therapeutic Approaches 2.0)
►▼ Show Figures

Figure 1

15 pages, 2118 KiB  
Article
Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients
by Gregorio Di Franco, Alice Usai, Margherita Piccardi, Perla Cateni, Matteo Palmeri, Luca Emanuele Pollina, Raffaele Gaeta, Federica Marmorino, Chiara Cremolini, Luciana Dente, Alessandro Massolo, Vittoria Raffa and Luca Morelli
Biomedicines 2022, 10(7), 1474; https://doi.org/10.3390/biomedicines10071474 - 22 Jun 2022
Cited by 8 | Viewed by 1937
Abstract
The use of zebrafish embryos for personalized medicine has become increasingly popular. We present a co-clinical trial aiming to evaluate the use of zPDX (zebrafish Patient-Derived Xenografts) in predicting the response to chemotherapy regimens used for colorectal cancer patients. zPDXs are generated by [...] Read more.
The use of zebrafish embryos for personalized medicine has become increasingly popular. We present a co-clinical trial aiming to evaluate the use of zPDX (zebrafish Patient-Derived Xenografts) in predicting the response to chemotherapy regimens used for colorectal cancer patients. zPDXs are generated by xenografting tumor tissues in two days post-fertilization zebrafish embryos. zPDXs were exposed to chemotherapy regimens (5-FU, FOLFIRI, FOLFOX, FOLFOXIRI) for 48 h. We used a linear mixed effect model to evaluate the zPDX-specific response to treatments showing for 4/36 zPDXs (11%), a statistically significant reduction of tumor size compared to controls. We used the RECIST criteria to compare the outcome of each patient after chemotherapy with the objective response of its own zPDX model. Of the 36 patients enrolled, 8 metastatic colorectal cancer (mCRC), response rate after first-line therapy, and the zPDX chemosensitivity profile were available. Of eight mCRC patients, five achieved a partial response and three had a stable disease. In 6/8 (75%) we registered a concordance between the response of the patient and the outcomes reported in the corresponding zPDX. Our results provide evidence that the zPDX model can reflect the outcome in mCRC patients, opening a new frontier to personalized medicine. Full article
(This article belongs to the Special Issue Colorectal Cancer: New Diagnostic and Therapeutic Approaches 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop